We are excited to share a collaborative study, published in Cell Reports: “Topoisomerase I inhibition yields a CD74high/MHChigh human microglial subtype with enhanced Aβ uptake” (Haage …

Bhattarai, Yilmaz and colleagues identify astrocyte-derived fibronectin as a key driver of blood–brain barrier dysfunction in Alzheimer’s disease, linking APOE ε4 and amyloid pathology to vascular dam...

Kaur–Trautmann et al. present a high-throughput, chemically defined 3D glioblastoma model based on glycosaminoglycan hydrogels that allow orthogonal control of stiffness, adhesion, and degradability ...

We are pleased to highlight a recent publication by Ray et al. (2025) that investigates local genetic covariance between early-onset Alzheimer’s disease (EOAD) and blood lipid traits. We in the Kiz…

The apolipoprotein E4 allele (APOEϵ4) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD), yet its molecular impact on cerebrovascular biology remains inconclusive, particular...

Although the heart has its own nervous system, its organization and functionality remain largely unknown. Here, the authors reveal the molecular, chemical, and functional diversity of neurons within t...

Although the heart has its own nervous system, its organization and functionality remain largely unknown. Here, the authors reveal the molecular, chemical, and functional diversity of neurons within t...

We are thrilled to announce our participation in a groundbreaking study in collaboration with Mayo Clinic, now published in Nature Communications. This research looks into the intricate role of blo…

We are glad to announce that we received a Translational Therapeutics Accelerator (TRx) Pilot Award, which provides resources to position therapeutic discoveries for future commercial value. T…

In this study, Tayran et al. investigate the role of ABCA7, certain genetic variants of which act as risk factors for Alzheimer’s disease (AD), using a zebrafish AD model. They demonstrate that ABCA7-...

Variants of the ABCA7 gene accelerate neurodegeneration by reducing the amount of neuropeptide Y, a protein essential for maintaining brain synapses.

We discovered a genetic variant that reduces the odds of developing Alzheimer’s disease by up to 70% and may be protecting hundreds of thousands of people from the disease. The discovery of the pro…

We are proud to announce that our recent publication where we identified a protective genetic variant in FN1 gene against Alzheimer’s disease received a recognition award from McAlpine Founda…